Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Deals

Immetas measures up to $11m
Morningside Ventures has thrown its weight behind the Harvard spinout, which hopes to develop bi-specific antibodies to treat age-driven cancers and inflammatory diseases.
Snyk executes purchase of DeepCode
The ETH Zurich software security spinout had raised at least $5.2m before it was purchased by Snyk yesterday for an undisclosed sum.
Siolta surges to $30m series B
UCSF spinout Siolta Therapeutics picked up SymBiosis and Kirin Holdings in a round set to fund efficacy trials of its potential asthma treatment.
Daily deal net: September 23, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Polyneuron binds in extra series A cash
HBM Healthcare chipped in additional funding to bring University of Basel spinout Polyneuron's series A round to $39.7m.
Beyond Limits lines up $133m series C
Group 42 and BP Ventures have co-led a series C round for Caltech and Nasa spinout Beyond Limits, with $113m already closed.
Virogin Biotech transmits $62m series C
Backed by Shanghai Fudan University previously, Virogin Biotech will invest the series C proceeds in its clinical drug programmes and securing industry partnerships.
Daily deal net: September 22, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

News Continued

Daily deal net: September 21, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Athira attains $204m IPO
The Washington State University neurological drug developer has gone public after issuing 12 million shares priced at $17 each.
Baijiayun basks in $26.3m series B
Cash Capital was among the investors for Baijiayun, creators of an online education and training platform tailored to delivering massively open online courses.
Roche fires up $448m Inflazome acquisition
Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.
Daily deal net: September 18, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Corporates floor Lava with $83m
Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer, which builds on work at Amsterdam UMC.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
test reg

Login